Lupin Limited has announced that results from its ongoing Phase 1a clinical trial evaluating LNP8701, a novel SOS1 inhibitor for metastatic solid tumors, have been accepted for publication at the ASCO Annual Meeting 2026 being held from May 29 to June 2, 2026.

The abstract, titled “A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors”, has been published under the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track.

LNP8701 is an orally administered investigational therapy designed to inhibit SOS1 (Son of Sevenless1), a key mediator of RAS activation associated with oncogenic signaling and tumor growth. The first-in-human study is evaluating the drug’s safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced solid tumors.

According to the findings presented in the abstract, LNP8701 demonstrated a favourable safety and pharmacokinetic profile across all tested dosing levels and showed encouraging early anti-tumor activity. Preliminary efficacy data revealed that two patients completed 12 cycles of LNP8701 monotherapy, equivalent to one year of treatment, while another patient completed 14 cycles with stable disease.

Vinita Gupta, CEO, Lupin said, “The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers. We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes.”

Lupin stated that the company will continue evaluating LNP8701 in an ongoing Phase 1b clinical trial in India and further explore its potential both as a standalone therapy and in combination treatment approaches for solid tumors.

The abstract has been published in the Journal of Clinical Oncology supplement under Abstract Number e15162. The clinical trial is registered under CTRI/2024/08/072373.